PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34478015-3	2022	We estimated the relative prevalence of high adherence (intracellular tenofovir-diphosphate concentration >= 700 fmol/punch) 3- and 6-months after PrEP initiation among those who disclosed vs. did not disclose their PrEP use, both overall and by age.	tenofovir diphosphate	70-91	prolyl endopeptidase	Homo sapiens	147-151	
34478015-3	2022	We estimated the relative prevalence of high adherence (intracellular tenofovir-diphosphate concentration >= 700 fmol/punch) 3- and 6-months after PrEP initiation among those who disclosed vs. did not disclose their PrEP use, both overall and by age.	tenofovir diphosphate	70-91	prolyl endopeptidase	Homo sapiens	216-220	
35239448-6	2022	PrEP adherence was measured at week 48 using intracellular tenofovir-diphosphate drug concentrations.	tenofovir diphosphate	59-80	prolyl endopeptidase	Homo sapiens	0-4	
32766890-2	2021	Tenofovir diphosphate (TFV-DP) concentrations in TGW and transgender men (TGM) using gender affirming hormones and on directly observed dosing of PrEP have not been studied.	tenofovir diphosphate	0-21	prolyl endopeptidase	Homo sapiens	146-150